The Latest Breaking News from Stryker

This article highlights three MedTech stocks poised for growth in 2025

Stryker has substantially outpaced other medical device stocks over the past year and analysts remain strongly bullish on the stock’s prospects.

Ratings for Stryker (NYSE:SYK) were provided by 19 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Medtech giant Stryker has outperformed the broader market over the past year, and analysts remain moderately bullish on the stock’s prospects.

A Relative Strength Rating upgrade for Stryker shows improving technical performance.

The medical device sector is evolving, driven by rising demand for precision technology in diagnostics. Therefore, it could be ideal to buy fundamentally solid medical device stocks Stryker Corp (SYK), Axogen (AXGN), and Zimmer Biomet Holdings (ZBH), which look poised for substantial growth. Read more….

Stryker shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Stryker is set to release its Q3 earnings next week, and analysts forecast a lower-double-digit rise in profits.

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

Summary Stryker Corporation (SYK) shows strong technical buy signals, with a 6.09% gain since 8/21, and consistent price appreciation across key moving averages. The company operates in MedSurg, Neurotechnology, Orthopaedics, and Spine segments, offering a wide range of medical devices and technologies. Analysts provide mixed ratings, with price targets ranging...

Despite Stryker’s outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.